[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1997

Prognostic Significance of Coexistent Bulky Metastatic Central Nervous System Disease in Patients With Leptomeningeal Metastases

Author Affiliations

From the University of California, San Diego. Dr Chamberlain is now affiliated with Kaiser Permanente Southern California, Baldwin Park.

Arch Neurol. 1997;54(11):1364-1368. doi:10.1001/archneur.1997.00550230037013
Abstract

Objective:  To assess the clinical significance of bulky metastatic central nervous system disease in patients with leptomeningeal metastases.

Patients and Methods:  Forty patients (24 women and 16 men) ranging in age from 32 to 74 years (median, 56.5 years) with cytologically documented leptomeningeal metastases were demonstrated by cranial or spinal magnetic resonance imaging to have either no bulky central nervous system metastatic disease (group A; 20 patients) or bulky central nervous system metastatic disease (group B; 20 patients). Twenty-nine patients were treated with involved-field radiotherapy, and all patients were treated with sequential intraventricular chemotherapy.

Results:  Median survival was 7 months in group A (range, 5-12 months) as compared with 4 months in group B (range, 2-12 months) (P<.01; Mantel-Cox log rank analysis). Cause of death was similar in both patient groups.

Conclusions:  In patients with leptomeningeal metastases, neuroradiographic demonstration of bulky metastatic central nervous system disease independently predicts survival and is useful in determining which patients are candidates for intraventricular chemotherapy.

×